Mirae Asset Global Investments Co. Ltd. Acquires 52,099 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Mirae Asset Global Investments Co. Ltd. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 52,099 shares of the medical equipment provider’s stock, valued at approximately $4,628,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC grew its holdings in Zimmer Biomet by 11.5% during the 3rd quarter. ProShare Advisors LLC now owns 41,337 shares of the medical equipment provider’s stock valued at $3,672,000 after purchasing an additional 4,249 shares during the last quarter. Vise Technologies Inc. bought a new stake in Zimmer Biomet during the 3rd quarter valued at $268,000. Grandfield & Dodd LLC raised its holdings in shares of Zimmer Biomet by 80.5% in the third quarter. Grandfield & Dodd LLC now owns 20,823 shares of the medical equipment provider’s stock valued at $1,818,000 after acquiring an additional 9,284 shares in the last quarter. Cidel Asset Management Inc. bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $207,000. Finally, MGO One Seven LLC lifted its holdings in Zimmer Biomet by 21.1% during the third quarter. MGO One Seven LLC now owns 5,884 shares of the medical equipment provider’s stock worth $523,000 after buying an additional 1,024 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Down 2.8%

Shares of NYSE ZBH opened at $107.08 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $112.54. The company’s 50-day simple moving average is $95.01 and its 200-day simple moving average is $91.99. The company has a quick ratio of 0.94, a current ratio of 1.46 and a debt-to-equity ratio of 0.49. The firm has a market cap of $20.42 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 2.65 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The business had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet’s third-quarter sales of $2.063 billion and adjusted EPS of $1.90 topped analyst estimates. The company also raised its full-year 2026 outlook; hip and S.E.T. sales helped offset softer knee results. Third-quarter results
• Positive Sentiment: Analysts raised targets, with UBS moving to $130 and keeping a Buy rating, and RBC increasing its target to $125 with an Outperform rating. These revisions signal improved expectations for the shares. UBS analyst rating
• Neutral Sentiment: JPMorgan, Citi, and Wells Fargo also lifted their price targets, but retained Neutral or Equal Weight ratings. Bernstein raised its target to $107 while maintaining Market Perform, reflecting a more cautious view.
• Negative Sentiment: Knee-market challenges and margin pressure temper the results. Reported diluted EPS fell 13.8% year over year to $1.00, although adjusted EPS was flat at $1.90, so investors may weigh the outlook improvement against operating pressures. Quarterly outlook and knee-market challenges

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ZBH shares. UBS Group raised their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company a “buy” rating in a report on Thursday. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $111.95.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.